Keywords: European Union, CHMP opinions, Hospira, Filgrastim, Vaccines, Roche, OSI, Tarceva, Influenza,
Europe’s advisory body CHMP updates on pandemic medicines, backs Hospira’s biosimilar filgrastim and several generics and clears added use for Tarceva
Article | 22 March 2010
Following three days of meetings last week, the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
